TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
The American College of Cardiology (ACC) has published a new guidance document focused on the treatment of patients who present with atherosclerotic cardiovascular disease (ASCVD) and other chronic conditions sch as hypertension, diabetes and atrial fibrillation (AFib).

An eye on imaging: How to limit radiation exposure during TAVR procedures

Specialists at a high-volume facility in Germany were able to successfully limit radiation dose—and patient outcomes did not suffer. 

December 22, 2020

Skip the clopidogrel? TAVR patients benefit from antiplatelet therapy that includes aspirin only

The risk of major bleeding or life-threatening bleeding events was higher when clopidogrel was included in the patient's treatment strategy. 

December 9, 2020
business news announcement

Boston Scientific to retire Lotus Edge TAVR program after voluntary recall

The company will now focus its attention on the marketing and development of other solutions.

November 17, 2020
heart.png

TAVR stands tall as ‘the dominant form of aortic valve replacement,’ specialty groups declare

Specialists from the American College of Cardiology and Society of Thoracic Surgeons explored data from more than 276,000 patients who have undergone a TAVR procedure in the last nine years. 

November 16, 2020

Wait times for TAVR, SAVR patients are getting longer and longer

The study’s authors tracked data from more than 22,000 patients with severe aortic stenosis.

November 12, 2020

Among TAVR patients with AFib, DOACs lead to better survival rates than vitamin K antagonists

However, the two treatment options were associated with similar rates of long-term bleeding and ischemic events. 

November 6, 2020

New meta-analysis compares early TAVR outcomes for Sapien 3, Evolut valves—and spots some key differences

The new study focused on the early outcomes of more than 24,000 patients who participated in a total of nine different studies.

November 3, 2020

Embolic protection devices fail to limit death or stroke among TAVR patients

The meta-analysis, published in the American Journal of Cardiology, explored data from six different randomized trials. 

October 26, 2020
Displaying 305 - 312 of 340
Design by Adaptive Theme